SOUTH SAN FRANCISCO, Calif., June 3 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the expansion of its late-stage development leadership team with the appointment of industry veterans Steven B. Ketchum, Ph.D., as Senior Vice President, Research and Development and Mary G. Bolton, M.D., Ph.D., as Vice President, Clinical Development. In addition, Judith A. Fox, Ph.D., has been promoted to Vice President, Product and Preclinical Development and Glenn C. Michelson, M.D., has been promoted to Vice President, Clinical Strategy.
"As our lead anti-cancer product candidate, voreloxin, continues to demonstrate promising clinical activity and a consistent safety profile in both acute myeloid leukemia and ovarian cancer, we are excited to welcome Drs. Steve Ketchum and Mary Bolton to Sunesis," said Daniel Swisher, Sunesis' Chief Executive Officer. "We are also pleased to announce the promotions of Drs. Judy Fox and Glenn Michelson. Judy and Glenn have made tremendous contributions to our voreloxin development program. Collectively, the extensive product development and regulatory expertise of this expanded leadership team will be a tremendous asset as we prepare for the expected initiation of late-stage trials for voreloxin next year."
"With the promising clinical activity and safety profile seen to date for voreloxin, I am excited by the opportunity to lead Sunesis' talented development organization as we advance this first-in-class product candidate into its next phase of development," said Dr. Ketchum.
Dr. Ketchum brings more than fifteen years experience in late-stage
product development and clinical regulatory strategy, having led the
filings of multiple successful New Drug Applicati
|SOURCE Sunesis Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved